AGP Executive Report
Last update: 9 hours agoBiotech & Licensing: IMPACT Therapeutics and Pharmanovia signed an exclusive deal for senaparib (PARP inhibitor) covering the EU, UK, Norway, Iceland, Liechtenstein and Switzerland, plus MENA, Australia and New Zealand, with total potential value up to €423.5M and royalties up to the mid-20% range. EU Health Regulation: Pfizer and BioNTech secured European Commission marketing authorisation for an XFG-adapted COVID-19 vaccine, valid across the EU plus Iceland, Liechtenstein and Norway. Energy & Supply Chains: Europe’s heatwave and drought are forcing Hungary to cut nuclear output as Danube levels hit record lows, threatening industrial activity and major shipping routes. Border Tech & Travel Rules: The EU’s Entry/Exit System (EES) is rolling out at Spain’s Port of Bilbao, while ETIAS is delayed to 2027—important for cross-border mobility and logistics. Crypto Compliance: Binance reportedly vanished from Google Play in some EU markets amid MiCA-related compliance changes. Business Finance & Industry Support: The European Commission plans interest-free EUR 1.5bn loans to scale EV battery production, with funding for projects up to 60% of eligible costs. Football Governance & Investment: UEFA confirmed it will boycott FIFA competitions if Infantino’s plan to sell World Cup stakes to private investors goes ahead, with Liechtenstein among the countries listed as affected.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
